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Circulating leukocytes leave the intravascular compartment via
events that include the participation of sequentially-acting leuko-
cyte-endothelial adhesion receptor-counter-receptor pairs [re-
viewed in I]. Initial events in this process are characterized by
oligosaccharide-dependent adhesive interactions. In the context
of vascular shear flow, these interactions promote the rolling of
leukocytes along the endothelial surface of the blood vessel
interior. Leukocyte rolling is in turn a prerequisite for subsequent,
activation-dependent events leading to integrin-mediated leuko-
cyte arrest, and endothelial transmigration.
Leukocyte rolling is a property characteristic of adhesion
mediated by E-, P-, and L-selectins. As will be detailed below,
these glycoproteins express structurally similar NH2-terminal
carbohydrate binding domains, are encoded by closely linked loci,
and maintain similar, though distinct counter-receptor require-
ments [1, 2]. Given the important role assigned to selectin-
dependent leukocyte adhesion in inflammation, and attendant
opportunities for therapeutic intervention in inflammation-de-
pendent pathology, there has been a substantial amount of
interest in defining the molecular nature of the ligands for E-, P-,
and L-selectins. This manuscript will outline the current under-
standing of the molecules that function as selectin ligands, and on
how the construction of these molecules is accomplished, and
regulated, especially via the actions of a specific a(1,3)fucosyl-
transferase termed Fuc-TVII.
L-selectin ligands
Mammalian lymphocytes recirculate between the intravascular
compartment and the lymphatic system. Lymphocytes leave the
vascular tree within lymph nodes, and other lymphoid aggregates
like Peyer's patches [reviewed in 1, 3, 41. Lymphocytes that have
emerged into these secondary lymphoid organs pass through the
parenchyma of the lymphoid aggregate, travel in the lymphatic
ductal system, and return to the vascular tree at the thoracic duct.
The lymphocyte recirculatory system facilitates lymphocyte en-
counters with foreign antigens within the lymphatic organs, and
comprises an essential part of the normal immune system. Lym-
phocytes depart the circulation through adhesion-dependent pro-
cesses occurring in the postcapillary venules of secondary lym-
phoid organs. The initial events in this process, especially with
respect to lymphocyte homing to peripheral lymph nodes, are
characterized by adhesion between L-selectin expressed by the
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lymphocytes, and L-selectin counter receptors expressed by spe-
cialized endothelial cells lining the postcapillary venules [reviewed
in 1, 3]. These specialized postcapillary venular endothelial cells
are cuboidal in shape, and are functionally distinct from typical
vascular endothelia. The venules lined with these cells are termed
high endothelial venules, or HEVs. Lymphocyte homing to the
peripheral lymph nodes is mediated in large measure by oligosac-
charide-dependent adhesive processes that occur between circu-
lating lymphocytes and the peripheral node HEV (PNHEV).
Functional assays reflective of lymphocyte homing include the
Stamper-Woodruff assay [5]. This assay involves application of
lymphocytes to HEVs exposed at the surface of a frozen section of
a peripheral lymph node. Adherent cells remaining attached to
the HEV after washing are quantitated, as a reflection of lympho-
cyte adhesion to the exposed HEy. This assay was used together
with biochemical and immunologic approaches to identity a
lymphocyte cell surface antigen, recognized by the monoclonal
antibody MEL-14, that mediates lymphocyte adhesion to PNHEV
[6, 7]. The MEL-I 4 monoclonal antibody blocks lymphocyte
adhesion to PNHEV and inhibits homing of lymphocytes to the
peripheral lymph nodes in vivo [6].
Early studies provided circumstantial evidence for the possibil-
ity that MEL-14 mediates lymphocyte adhesion through recogni-
tion of carbohydrate determinants displayed by PNHEV [8, 9].
This hypothesis was prompted in part by the observation that the
surface of PNHEV is composed in part of a prominent glycocalyx,
and by the fact that glutaraldehyde fixation of the exposed
PNHEV, which generally leaves carbohydrate determinants in-
tact, while denaturing many polypeptide antigens, minimally
diminishes lymphocyte adhesion to PNHEV [5]. The notion that
MEL-14-dependent lymphocyte adhesion is dependent upon spe-
cific carbohydrate determinants was supported by a series of
experimental observations [8, 9] indicating that adhesion could he
blocked by some monosaccharides, and by experimental manipu-
lations involving removal of sialic acid moieties from the surface
of PNHEV with sialidases [9—I 1]. This work and other studies
[reviewed in 3] indirectly implicating the MEL-14 antigen as a
carbohydrate binding protein, implied that lymphocyte-PNHEV
adhesive interactions were mediated by the molecular interactions
between the adhesion molecule on lymphocytes recognized by the
MEL-14 monoclonal antibody, and sialylated carbohydrate-con-
taining counter-receptors on PNHEV.
Molecular cloning studies subsequently demonstrated that the
MEL-14 antigen corresponds to a protein now termed L-selectin
(cluster designation CD62L) [12—17]. The polypeptide sequence
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of the amino terminal domain of L-selectin is similar to a family
of proteins, termed C-type lectins, that exhibit calcium-dependent
carbohydrate binding properties [18]. This information provided
additional strong evidence that the calcium-dependent nature of
lymphocyte-PNHEV adhesive interactions was mediated through
L-selectin recognition of specific PNHEV-borne, carbohydrate-
containing counter-receptors.
More recent work illuminates the nature of a series of glyco-
proteins expressed by PNHEV that function as L-selectin counter-
receptors, and has identified candidate oligosaccharide structures
required for L-selectin-dependent recognition of these molecules.
Some of this work has employed a recombinant L-selectin-IgG
chimera as an immunohistochemical probe to explore the nature
of these ligands in tissues sections, and as an affinity purification
reagent for biochemical characterization [19, 20]. This work has
led to the molecular cloning of cDNAs encoding several PNHEV
glycoproteins with L-selectin counter-receptor activity. In immu-
nochemical studies, the L-selectin-Ig chimera immunoprecipitates
50 kDa and 90 kDa [35S]-labeled polypeptides in extracts pre-
pared from lymph nodes radiolabeled with [35S]sulfate [20—221.
Both immunoprecipitated molecules can be radiolabeled with
fucose, but not with rnannose or glucose, indicating that they are
sulfated, fucosylated glycoproteins. The inability to label these
molecules with mannose or glucose, together with the fact that
their electrophoretic mobilities were not altered by digestion with
N-glycanase, implied that the glycoproteins contain few, if any,
asparagine-linked (N-linked) oligosaccharides [23]. These data
suggest that most, and perhaps all, of the glycans displayed by
these two proteins are of the serine/threonine-linked type (0-
linked glycans). These molecules were initially termed Sgp5° and
Sgp90, for sulfated glycoprotein of 50 kDa and 90 kDa, respec-
tively. The L-selectin-IgG chimera immunoprecipitates Sgp5° and
Sgp9° even after their extraction from denaturing SDS polyacryl-
amide gels, implying that their recognition by the L-selectin-IgG
chimera occurs primarily through the glycan moieties. Similar
approaches identify a third molecule, termed Sgp200, with similar
biochemical properties, in lymph node extracts [24].
Sgp5° and Sgp9° have been purified, and cDNAs encoding these
molecules have been cloned [25, 26]. The Sgp5° cDNA predicts a
132 amino acid long polypeptide, known as G1yCAM-1, for
glycosylation-dependent cell adhesion molecule. The sequence
predicted for G1yCAM-1 includes numerous serine and threonine
residues with potential for modification by 0-glycosylation, but
only a single potential N-linked glycosylation site [25]. The
numerous serine and threonine residues, when considered to-
gether with the difference in size between the observed (—50,000
Da) and predicted (14,154 Da) molecular masses, suggests that
0-linked glycans make up a large portion of the glycoprotein's
size, and recommend it as a mucin-type glycoprotein. Immuno-
electron microscopy studies show that little, if any, G1yCAM-1 is
expressed at the surface of the HEy. However, it is certainly
released as a soluble molecule following passage through the
secretory pathway [27], confirming the observation that Gly-
CAM-i is detectable as a soluble entity in the conditioned
medium of lymph node organ cultures [25]. Absence of membrane
association is consistent with the absence of a clearly evident
membrane spanning domain within the peptide sequence of
GIyCAM-1. These observations suggest that G1yCAM-1 does not
directly mediate L-selectin-dependent adhesion of lymphocytes to
HEy. The function of this soluble counter-receptor for L-selectin
remains to be defined.
Protein sequence analysis of Sgp9° affinity purified from mouse
peripheral lymph nodes disclosed peptide sequences correspond-
ing to the previously cloned murine sialomucin molecule CD34
[261. The predicted structure of CD34 is similar to that of
GIyCAM-1 in that it contains numerous serine and threonine-
rich, mucin-like domains that are apparently heavily modified by
0-linked glycan structures. Biochemical analyses referred to
above [21, 24] indicates that the 0-glycans on PLN-derived
CD34/Sgp9° are sulfated, and, as with G1yCAM-l, are probably
essential to recognition by L-selectin. Since CD34 maintains a
single membrane-spanning domain that places the bulk of the
molecule on the extracellular face of the plasma membrane, it
seems probable that it figures importantly in the L-selectin-
dependent adhesion of lymphocytes to lymph node HEy.
Since CD34 is expressed by vascular endothelial cells, and by
many other tissues [28], it is possible that CD34 could operate as
an L-selectin counter-receptor to facilitate leukocyte-endothelial
cell interactions in acute and chronic inflammation (provided it
has been glycosylated appropriately). This notion has received
some support recently, through the observation that L-selectin-
dependent leukocyte rolling in vitro can be supported by some
glycoforms of CD34 in the human tonsil [29].
A third molecule, known as the mucosal vascular addressin
molecule MAdCAM-1, can also present oligosaccharide ligands
to L-selectin [30]. MAdCAM-1 functions as the counter-receptor
for the lymphocyte homing receptor a4137, and directs a large
fraction of the lymphocyte homing to Peyer's patches [31].
MAdCAM-l isolated from mouse mesenteric lymph nodes dis-
plays sialylated, N-glycanase-resistant glycans, and can support
L-selectin-dependent leukocyte rolling in vitro. By contrast, gly-
coforms of MAdCAM-1 isolated from cells where L-selectin-
dependent adhesion is not observed do not support L-selectin-
dependent leukocyte rolling. This work implies that tissue-specific
glycosylation of MAdCAM-1 determines its function as an L-
selectin counter-receptor. These observations additionally imply
that MAdCAM-1 can operate both as a counter-receptor for
shear-dependent adhesion processes (mediated by both L-selectin
and the a47 integrin), as well as a counter-receptor for subse-
quent firm attachment events (also mediated by a47 integrin).
The nature of the glycan moieties that clearly play an important
role in L-selectin-dependent interactions has also received a
considerable amount of recent attention. As noted above, early
studies implied a critical role for sialic acid moieties in these
interactions. Studies with sialidases with specificity for different
sialic acid linkages [that is, a(2,3), a(2,6), or u(2,8) linkages] imply
that sialic acid in a(2,3) linkage is essential to L-selectin counter-
receptor activity [32].
Indirect biochemical evidence implies that sulfate is also essen-
tial for L-selectin counter-receptor activity [331. This evidence
derives in part from the observation that a non-sulfated form of
GIyCAM-1 purified from PNHEVs treated with an inhibitor of
sulfation (chlorate) is not recognized by the L-selectin-IgG chi-
mera. Later work has demonstrated that L-selectin can bind to
both the a(2,3)sialylated tetrasaccharides sialyl Lewis a and sialyl
Lewis x [34, 35], as well as to isomers of these tetrasaccharides in
which the terminal a(2,3)-linked sialic acid residue has been
replaced by a sulfate group attached to the 3 hydroxyl of the
terminal galactose moiety [36]. Since it was known that these
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Fig. 1. Core 2-based 0-linked candidate L-selectin ligands. These structures derive from biochemical analysis of glycans displayed by mouse G1yCAM-1
[39].
oligosaccharides can also participate in E- and P-selectin-depen-
dent cell adhesion (detailed below), these observations suggested
that 0-glycans implicated in L-selectin counter-receptor activity
might include sulfated, a(2,3)sialylated, a(1,3)fucosylated glycans
with structural similarity to the sialyl Lewis x determinant and its
isomers. This notion was supported by evidence for expression of
immunochemically similar epitopes on human HEV [34, 37].
Structural analyses of the 0-linked glycans associated with
G1yCAM-1 have led to the identification of a pair of sulfated
forms of the sialyl Lewis x molecule as candidates for L-selectin
ligands [24, 38]. In these studies, four sulfated moieties (Gal-6-
SO4, GIcNAc-6-S04, [S04-6]Gal[3(1, 4)GlcNac, and Gal3(1,4)-
[S046]GlcNAc) were identified as components of the 35S04-
labeled oligosaccharides prepared from G1yCAM-1 derived from
lymph node organ cultures metabolically labeled with 35S04.
Lectin binding and glycohycirolase degradation experiments pro-
vided evidence that 6'-sulfo sialyl Lewis x (NeuNAca(2,3)[S04-
6]GaIf3(I,4)G1cNAc) is found as a major terminal component of
the GIyCAM-1 0-linked glycans [39]. Complementary studies
involving synthetic approaches to construct the isomeric pentasac-
charide 6-sulfo sialyl Lewis x (NeuNAca(2,3)Gal(1,4)[S04-
6][Fuca(1,3)]GlcNAc(1,3)Gal) demonstrate that this molecule
can inhibit binding of an L-selectin-lgG chimera to a heteroge-
neous preparation of glycoforms of Sgp50, Sgp90, Sgp20° with
L-selectin counter-receptor activity [40].
Additional structural analyses indicate that GIyCAM-1 displays
a pair of 0-linked oligosaccharides containing the 6-sulfo sialyl
Lewis x and 6'-sulfo sialyl Lewis x moieties. These oligosaccha-
rides derive from a core 2 0-glycan moiety, identified previously
as a component of 0-linked oligosaccharides in many mucin-type
glycoproteins (Fig. 1). Biosynthetic studies indicate that the
0-linked glycans associated with L-selectin counter-receptor ac-
tivity on GIyCAM-1 are constructed by an ordered series of
glycosylation reactions in which the component lactosamine
chains are most probably likely sialylated prior to sulfation and
fucosylation (Fig. 2) [41]. Although these experiments were not
able to define the relative order of addition of sulfate and fucose
to the a(2,3)sialylated precursor, previous studies with the
a(1,3)fucosyltransferases suggest that sulfation will precede fuco-
sylation [40, 42]. Furthermore, the physiological relevance of
fucosylation to L-selectin counter-receptor activity cannot be
determined from any of these studies, since it has not been
possible to purify and test GIyCAM-1 of other L-selectin counter-
receptors in a non-fucosylated but otherwise intact form.
Recent work indicates that a(1,3)fucosylation is essential to the
synthetic pathway that yields functional L-selectin counter-recep-
tors, and implies an essential role for the cs(1,3)fucosyltransferase
Fuc-TVII in this process [43, 44]. Fuc-TVII is expressed in murine
PNHEV, as well as in the HEV in mouse mesenteric nodes and
Peyer's patches [43]. In the mouse, ablation of the gene encoding
this enzyme through the use of gene "knock out" approaches
creates a deficit in the expression of L-selectin counter-receptor
activity in PNHEV, as well as in mesenteric node HEV and
Peyer's patches HEy, as determined with the use of an L-selectin-
1gM immunohistochemical probe. The deficit in L-selectin
counter-receptor activity is accompanied by a deficit in lympho-
cyte homing to peripheral lymphoid aggregates, and by a gener-
alized decrease in the lymphocyte cellularity of the peripheral
nodes in these mice [44]. The biochemical basis for these defects
are accounted for in part by results of fucosyltransferase assays
which demonstrate that mouse Fuc-TVII can form both sialyl
Lewis x and 6-sulfo sialyl Lewis x determinants, but not the
6'-sulfo sialyl Lewis x, from their respective non-fucosylated
precursors [43, 44]. These observations provide additional evi-
dence that the 6-sulfo sialyl Lewis x determinant is expressed by
HEy, and imply that this glycan is synthesized via an ordered
process involving sialylation, followed by sulfation, and termi-
nated by a(1,3)fucosylation. These experiments further imply that
(1,3)fucosylated glycans are essential to L-selectin counter-
receptor activity, and demonstrate that Fuc-TVII is essential to
this process. This proposed pathway for 6-sulfo sialyl Lewis x
biosynthesis must still be confirmed using purified sulfotrans-
ferase(s), and authentic acceptor substrates endogenous to the
HEy, and through structural analyses of authentic, HEV-born
oligosaccharide ligands for L-selectin. Moreover, the relevance of
the 6'-sulfo sialyl Lewis x moiety to L-selectin-dependent lympho-
cyte homing pathways remains to be defined, as does the biosyn-
thetic pathway for this molecule.
It should be noted that L-selectin also participates in neutrophil
and monocyte rolling through adhesive interactions with counter-
receptors displayed by endothelial cells and by other, adherent
leukocytes [45]. The nature of the ligands involved in these
interactions remains obscure.
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Fig. 2. Synthesis of candidate L-selectin ligands. Capping Structures proposed as ligands for L-selectin are displayed at the top (6-sulfo sialyl Lewis x and
6' -sulfo sialyl Lewis x), together with the related structure sialyl Lewis x, an essential component of the human leukocytic ligands for E- and P-selectins.
Possible biosynthetic routes are indicated by the bold arrows. These pathways begin with an a(2,3)sialylated lactosamine-based precursor (bottom)
displayed by 0-linked glycans of the form illustrated in Figure 1 (that is, r = core 2-type, 0-linked glycans). This precursor may be directly fucosylated
by Fuc-TVII to form the sialyl Lewis x moiety (center pathway), or it may be sulfated to form monosialylated, monosulfated structures. In vitro studies
summarized in the text indicate that Fuc-TVII can form the 6-sulfo sialyl Lewis x structure from one such precursor (pathway at left). A monosialylated,
monosulfated potential precursor to the 6'-sulfo sialyl Lewis x structure is not utilized in vitro, by Fuc-TVII, or any known a(1,3)fucosyltransferase, to
form the 6'-sulfo sialyl Lewis x moiety (pathway at the right hand side of the figure). It is possible that the sialyl Lewis x determinant is a substrate for
sulfotransferase activities (sulfo-T) that may construct the 6-sulfo sialyl Lewis x structure (top left), or the 6'-sulfo sialyl Lewis x structure (top right),
or a 6'6-disulfo sialyl Lewis x structure (not shown). Also not shown is a di-sulfated, monosialylated structure possibly formed by such enzymes, which
could be used subsequently by Fuc-TVII, or other a(1,3)fucosyltransferases, to form a 6'6-disulfo sialyl Lewis x structure (also not shown).
E-selectin ligands
The biology of the endothelial cell adhesion molecule E-
selectin (formerly termed endothelial cell adhesion molecule 1, or
ELAM-1; cluster designation CD62E) has been reviewed [1, 46].
E-selectin, like L-selectin, maintains an amino terminal domain
that shares primary sequence similarity with the C-type lectins,
including the L-selectin lectin domain. E-selectin is an inducible
cell adhesion molecule expressed by capillary endothelial cells in
rheumatoid arthritis [47], sepsis [48], skin inflammation [49—531,
in some circumstances in association with organ transplant rejec-
tion [54], and in other acute and chronic inflammatory disorders.
Counter-receptors recognized by E-selectin are expressed by
neutrophils [55], monocytes [55], eosinophils [56], memory T-
lymphocytes [51, 57], and natural killer cells (NK cells) [58]. Since
these leukocytes are causally associated with inflammatory cir-
cumstances in association with E-selectin expression, it is virtually
certain that their recruitment to inflammatory sites involves
E-selectin-dependent adhesion processes. Characterization of
mice deficient in E-selectin confirms a critical role for E-selectin
in acute inflammatory models [59, 60], although a role for
E-selectin in chronic inflammation remains to be studied with
these animals.
Candidate counter-receptors for E-selectin were sought by
several groups among oligosaccharide structures displayed by
myeloid-lineage cells, but not by red cells, and included a large set
of fucosylated, sialylated oligosaccharides [61—64]. These glycans
were covalently associated with leukocyte glycoproteins and gly-
colipids that contain monomeric or polymeric lactosamine cores
[Gal/3(1,4)GlcNAc/3(1,3)Gal]. Leukocyte polylactosamines may
exist unmodified, but are often instead modified by terminal or
subterminal substitution with sialic acid, in either a(2,3)-linkage
or s(2,6)-linkage, or by a(1,3)-linked fucosylation. As a(1,3)-
linked fucosylation is typical of leukocyte glycans, but not red cell
glycans, this modification was considered a likely component of
candidate E-selectin ligands.
The sialyl Lewis x structure (Fig. 2) represents the prototype of
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lactosamine-based oligosaccharides generated by a(2,3)sialyla-
tion, and a(1,3)fucosylation. Isomers of these structures also
found in leukocyte glycans include structures that are internally
and/or multiply a(1,3)fucosylated [64—67]. A number of studies
have demonstrated an important and perhaps essential role for
the sialyl Lewis x determinant as a ligand for E-selectin, while
excluding the non-sialylated Lewis x structure as a ligand [68 —73].
Other work indicates that mono- and polyfucosylated variants of
the sialyl Lewis x structure found in leukocytes can also mediate
E-selectin-dependent cell adhesion [66, 671.
Biochemical data indicate that effective "presentation" by sialyl
Lewis x-type structures by a leukocyte is in large measure a
property subsumed by specific leukocyte cell surface molecules.
For example, neutrophil L-selectin is decorated with sialyl Lewis
x-containing glycans, and exhibits a relatively high affinity for
E-selectin [74]. Moreover, there is evidence that leukocyte L-
selectin is localized to the neutrophil microvilli, where it is
afforded a special opportunity to "present" oligosaccharide li-
gands to E-selectin in a manner that facilitates E-selectin-depen-
dent neutrophil rolling [75]. This work implies that specific
leukocyte cell surface glycoproteins have evolved in concert with,
or have been chosen by, selectin ligand synthetic processes, in
order to effectively present a ligand to E-selectin by virtue of their
topographical location in the plasma membrane, and perhaps by
other properties, including their abundance and/or structure.
Two other specific glycoproteins identified as counter-receptors
for E-selectin include PSGL-1, a polypeptide identified as a
leukocyte counter-receptor for P-selectin [76—79] (discussed be-
low), and ESL-1 (E-selectin ligand 1) [78, 80, 81], a widely-
expressed murine glycoprotein similar to a Golgi-localized
polypeptide assigned a role as a fibroblast growth factor binding
protein [82]. It is now clear that neutrophil PSGL-1 and ESL-1
each display a(2,3)sialylated, a(1,3)fucosylated, oligosaccharide
chains [81, 831 that are required for promoting effective E-
selectin-dependent leukocyte adhesion [77, 84, 85].
P-selectin ligands
P-selectin (CD62P), formerly known as granule membrane
protein (GMP-140) [86], or platelet activation-dependent granule
to external membrane protein (PADGEM) [87], is a 140 kDa
glycoprotein found in platelet a-granules [86, 87], in megakaryo-
cytes [88], and in the Weibel-Palade bodies of vascular endothelial
cells [89, 90]. P-selectin is released from these intracellular
locations less than 10 minutes after stimulation with thrombin
(platelets and endothelial cells) [87], or histamine, phorbol ester,
or the calcium ionophore A23187 (endothelial cells) [91]. Expres-
sion of P-selectin is also under transcriptional control in endothe-
hal cells, through mechanisms involving tumor necrosis factor a
[92] and other inflammatory mediators [reviewed in 2]. Constitu-
tive levels of P-selectin are also found in vivo, at a level that can
promote leukocyte rolling [93]. P-selectin-dependent leukocyte
adhesion occurs in a variety of acute and chronic inflammatory
circumstances [reviewed in 2]. Mice deficient in P-selectin are
defective in leukocyte rolling and emigration in acute inflamma-
tory models [59, 94—96].
P-selectin maintains an amino terminal domain with primary
sequence similarity to the corresponding domains of E- and
L-selectins [92, 97], and mediates calcium-dependent leukocyte
adhesion [98—100]. The structural similarity of P-selectin to L-
and E-selectins, together with an ability to interact with leukocytes
shared by E-selectin, focused efforts to identify oligosaccharides
as components of its counter-receptor(s). These efforts demon-
strated that the sialyl Lewis x moiety, and perhaps its variants,
represents an important component of P-selectin counter-recep-
tor activity [72, 101]. Subsequent work indicates that effective
P-selectin ligand activity is associated with sialyl Lewis x-type
structures associated with a specific leukocyte polypeptide termed
P-selectin glycoprotein ligand (PSGL-1; noted above) [77, 83].
Although PSGL-1 is widely expressed by blood leukocytes [85],
this 120 kDa mucin type transmembrane protein is functional as a
counter-receptor for P-selectin only when modified by sialylated,
a(1,3)fucosylated 0-linked glycans [76, 84]. Structural analysis
confirms that these structures include the sialyl Lewis x tetrasac-
charide as a terminal moiety [102]. Recent studies also demon-
strate that sulfation of one or more of the three tyrosine residues
near the NH2-terminus of PSGL-1 is essential for recognition by
P-selectin [103—105]. A second leukocyte molecule known as heat
stable antigen (cluster designation CD24) can also function as a
PSGL-1 counter-receptor [106].
Fucosyltransferases involved in leukocyte E- and P-selectin
ligand synthesis
The glycoproteins noted above that function as E- and P-
selectin ligands clearly must maintain properly decorated by
post-translational modifications in order to be recognized by these
two selectins. In particular, it is clear that a (1,3)fucosylation of
the oligosaccharides covalently associated with these glycopro-
teins is essential to their ability to function as E- and/or P-selectin
ligands [76, 77, 81, 84].
Modification of a(2,3)sialylated glycan chains by a(1,3)-linked
fucosylation of precursor glycans is directed by the action of one
or more distinct a(1,3)fucosyltransferases [reviewed in 107].
These enzymes act as the terminal event in the biosynthesis of
a(1,3)fucosylated glycans. Biochemical and genetic data [re-
viewed in 107] indicate that expression of these leukocyte
a(1,3)fucosylated structures is dictated by regulated expression of
a(1, 3)fucosyltransferase genes. Five such genes, termed Fuc-Till,
Fuc-TIV, Fuc-TV, Fuc-TVI, and Fuc-TVII, have now been iden-
tified through molecular cloning procedures [reviewed in 107].
Fuc-TIV (also known as ELFT, for ELAM-l Ligand Fucosyl
Iransferase) and Fuc-TVII are expressed in leukocytes [43, 68,
70, 108—111], and have represented important candidate enzymes
for controlling the synthesis of a(1, 3)fucosylated oligosaccharides
and selectin ligands in leukocytes.
Given that these enzymes will apparently control selectin ligand
expression, it has become important to define the relative roles of
these two candidate enzymes in this process. This is especially true
of the pharmaceutical industry, in consideration of the possibility
pharmacological inhibition of leukocyte-specific a(1,3)fucosyl-
transferases will lead to an anti-inflammatory outcome by virtue
of decreasing expression of functional leukocyte selectin ligands.
Fuc-TVII can clearly construct the sialyl Lewis x determinant in
vitro, as well as in cultured cell lines transfected with expression
vectors encoding this enzyme [43, 107, 110], and can also direct
expression of E- and/or P-selectin ligands on transfected cells [84,
104, 105, 110, 112]. This enzyme is also implicated in the control
of expression of E-selectin ligands on human T-lymphocytes [112].
An essential role for this enzyme in the expression of functional
leukocyte E- and P-selectin activity derives from an analysis of
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mice made deficient in this enzyme through gene ablation ap-
proaches [441. Although the Fuc-TVII (—I—) mice develop and
breed normally, the neutrophils and monocytes in these animals
do not bind to chimeric mouse E-selectin-humari 1gM or mouse
P-selectin-human 1gM flow cytometry probes. Moreover, the
Fuc-TVII (—I—) leukocytes are severely deficient in their ability
to roll when assayed using intravital microscopy approaches. The
deficit in leukocyte rolling and E- and P-selectin ligand expression
in these mice is accompanied by a deficit in neutrophil mobiliza-
tion in response to an acute inflammatory challenge. It is virtually
certain that these deficits are a consequence of deficient fucosy-
lation of the glycans displayed by leukocyte E- and/or P-selectin
counter-receptor glycoproteins (ESL-1, PSGL-1, L-selectin, and
CD24), because the blood neutrophils and monocytes in the
Fuc-TVII (—/---) mice express essentially normal levels of these
four glycoproteins. These observations demonstrate that Fuc-
TVII is essential to the synthesis of functional E- and P-selectin
ligands in the mouse leukocyte, and imply that a(1,3)-linked
fucosylated glycans are essential to E- and P-selectin counter-
receptors' activities.
The Fuc-TVII (—/--) mice also maintain a circulating leukocy-
tosis, accounted for in large measure by an approximately seven-
fold increase in the number of circulating neutrophils. There are
substantial increases in the numbers of other blood leukocytes,
however. Since a circulating leukocytosis is also evident in P-
selectin-deficient mice [941 and in mice made deficient in both
E-selectin and P-selectin [59], the leukocytosis in the Fuc-TVII
(—I-—) mice provides additional support for the hypothesis that
the adhesive partnership between E- and P-selectins and their
leukocytic counter-receptors is required to maintain homeostasis
in the numbers of myeloid lineage leukocytes circulating in the
blood [95].
A role for Fuc-TIV is selectin ligand synthesis remains to be
defined. This enzyme does not consistently direct cell surface
expression of the sialyl Lewis x determinant and E-selectin ligands
when expressed in cultured cell lines [68, 69, 84, 108, 1131. The
variable ability of this enzyme to direct selectin ligand expression
is thought to be a function of the glycosylation phenotype of the
host cell line in which its ability to exhibit this property is assayed
[113]. The biochemical basis for this contingent synthetic capabil-
ity remains to be determined, however, and it is not known if
leukocytes express the glycosyltransferases and other molecules
required to support Fuc-TIV-dependent selectin ligand expres-
sion. These issues will likely be resolved through the creation and
analysis of mice made deficient in Fuc-TIV, together with studies
that will define the structures of the oligosaccharides displayed by
E- and P-selectin counter-receptors on the leukocytes of both the
wild-type and fucosyltransferase mutant mice.
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